[HTML][HTML] Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label …
L Horn, DR Spigel, EE Vokes, E Holgado… - Journal of clinical …, 2017 - ncbi.nlm.nih.gov
L Horn, DR Spigel, EE Vokes, E Holgado, N Ready, M Steins, E Poddubskaya, H Borghaei…
Journal of clinical oncology, 2017•ncbi.nlm.nih.govNivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell
Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate
017 and CheckMate 057) - PMC Back to Top Skip to main content NIH NLM Logo Access
keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC6075826
Other Formats PDF (1013K) Actions Cite Collections Share Permalink Copy RESOURCES …
Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate
017 and CheckMate 057) - PMC Back to Top Skip to main content NIH NLM Logo Access
keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC6075826
Other Formats PDF (1013K) Actions Cite Collections Share Permalink Copy RESOURCES …
Abstract
Purpose
Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies in previously treated patients with advanced squamous (CheckMate 017; ClinicalTrials. gov identifier:
ncbi.nlm.nih.gov